AC Immune Extends Research Collaboration with University of Pennsylvania Focusing on the Pathogenic Protein TDP-43, a Major Driver of Neurodegenerative Diseases
04 nov. 2021 06h00 HE
|
AC Immune SA
LAUSANNE, Switzerland, Nov. 04, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
New Data on AC Immune’s Abeta and pTau Clinical Programs in Alzheimer’s Disease To Be Presented at CTAD 2021
02 nov. 2021 07h30 HE
|
AC Immune SA
LAUSANNE, Switzerland, Nov. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today...
AC Immune Holds its Extraordinary General Meeting and Appoints Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors
29 oct. 2021 06h00 HE
|
AC Immune SA
Dr. Shaw is a pharmaceutical industry expert who has been involved in advancing more than 15 therapeutic products from first-in-human studies through commercialization Prof. Bütler is a leading...
AC Immune to Present at the Jefferies London Healthcare Conference
25 oct. 2021 07h00 HE
|
AC Immune SA
LAUSANNE, Switzerland, Oct. 25, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today...
AC Immune CEO Andrea Pfeifer Receives First SEF.WomenAward for CEO of the Year
03 sept. 2021 07h52 HE
|
AC Immune SA
LAUSANNE, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
AC Immune to Participate in Upcoming Virtual Investor Conferences in September
02 sept. 2021 07h00 HE
|
AC Immune SA
LAUSANNE, Switzerland, Sept. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today...
AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease
31 août 2021 07h30 HE
|
AC Immune SA
Top-line data from Lauriet Phase 2 trial of semorinemab in mild-to-moderate AD shows a statistically significant reduction on one of two co-primary endpoints, ADAS-Cog11 First evidence of clinical...
AC Immune Reports Second Quarter 2021 Financial Results and Provides Corporate Update
04 août 2021 07h00 HE
|
AC Immune SA
Announced strategic acquisition of industry-leading Parkinson’s disease vaccine and equity investment led by key investors in Covid-19 vaccine innovator BioNTech SE ACI-24 full Phase 1b results...
AC Immune Presents Full Phase 1b Results on Anti-Abeta Vaccine and Discusses its First-in-Class Diagnostic for Parkinson’s Disease at AAIC 2021
29 juil. 2021 07h30 HE
|
AC Immune SA
ACI-24 generated an encouraging immune response that correlated with a signal of target engagement in patients with Down syndrome (DS) Full Phase 1b results support the continued clinical development...
AC Immune Announces Strategic Acquisition of Industry-leading Parkinson’s Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH
27 juil. 2021 07h30 HE
|
AC Immune SA
All-stock transaction maintains AC Immune’s strong cash position USD 25 million private placement led by premier investor Athos Service GmbH Transactions expand and accelerate AC Immune’s...